Klinika odbudowy włosów prowadzona przez chirurga w Levent w Stambule od 2007 roku.
Zobacz wszystko →Prześlij 3–5 zdjęć. Osobista odpowiedź w ciągu 24 godzin — bez pośredników.
Zamów teraz →FUE, DHI lub Algorithmic FUE™ — dr Arslan rekomenduje na podstawie Twoich zdjęć i stadium Norwood.
Zamów ocenę → Wypróbuj kalkulator →Członek FUE Europe. Klinika akredytowana przez Ministerstwo Zdrowia. Levent, Stambuł — o 60–80% taniej niż w Wielkiej Brytanii czy USA.
Zobacz pakiet →Członek FUE Europe. Akredytacja Ministerstwa Zdrowia. 17+ lat. 3000+ zabiegów wykonanych osobiście. Jeden pacjent dziennie.
Pełny profil →Pobranie i kanały zawsze osobiście. Wszczepienie — w VIP osobiście, w Silver/Gold przez przeszkolony zespół pod jego nadzorem. Za każdy efekt osobista odpowiedzialność.
Przeczytaj filozofię →Bez ukrytych kosztów. Hotel, transfery, zabieg i opieka w jednej cenie.
Zobacz cennik →Silver · Gold · VIP — hotel 4/5-gwiazdkowy · transfery lotniskowe · PRP w cenie
Zobacz cennik → Kalkulator graftów →Każdy przypadek wykonany osobiście przez dr. Arslana Musbeha.
Pełna galeria →Nie każdy przypadek wymaga przeszczepu. Leczenie farmakologiczne, terapie i opcje specjalistyczne.
Przegląd →Przewodniki, narzędzia i treści eksperckie — autorstwa dr. Arslana Musbeha.
Wszystkie artykuły →Female hair transplant candidacy is assessed differently from male candidacy for one key reason: female hair loss patterns are more diffuse. In men, pattern baldness typically creates clearly defined bald zones with a dense donor. In women, the donor zone may be less dense if female androgenetic alopecia is diffuse.

Good female candidates have: stable hair loss over 12 months, preserved donor density at the back and sides of the scalp, a defined area of loss (not diffuse loss over the entire scalp), and realistic expectations about achievable density.
Women are not good candidates if: loss is diffuse across the entire scalp including the donor zone, the underlying cause is active autoimmune alopecia, or hair loss is active and accelerating. In these cases, medical management must precede surgery.
Most women seeking hair transplant have existing hair throughout the recipient zone — whether diffuse thinning or partial hairline loss. DHI (Direct Hair Implantation) is specifically designed for this scenario: the Choi implanter pen places grafts without pre-creating channels, eliminating the risk of damaging adjacent existing follicles.
DHI also enables unshaved procedures for most female cases — the existing hair is gently moved aside rather than cut. This allows women to maintain their hairstyle throughout the recovery period, with the transplanted hair growing in gradually and invisibly integrating with the existing hair.
For female patients who cannot tolerate any visible sign of surgery during recovery, unshaved DHI provides complete discretion. The procedure leaves no cut hair, no shaved zones visible, and no obvious sign that a procedure has taken place. The transplanted hair sheds at weeks 2–5 (shock loss) and regrows from month 3–4 — all while existing surrounding hair remains at its natural length.

Yes. Women are excellent candidates for hair transplant when their hair loss meets candidacy criteria: stable pattern, adequate donor density, and appropriate underlying cause (genetic, traction, or post-inflammatory). DHI technique is often preferred for women as it works between existing hairs without requiring full recipient zone shaving.
The main treatable causes are: female androgenetic alopecia (Ludwig pattern thinning), traction alopecia from tight hairstyles, and post-inflammatory hair loss (after inactive scarring alopecia). Diffuse telogen effluvium and active autoimmune alopecia are not treated surgically.
DHI technique can be performed without shaving the recipient zone in most female cases — grafts are placed between existing hairs. During recovery, shock loss is less visible because existing surrounding hair is uncut. The result integrates naturally with existing hair over 10–12 months.
All references are peer-reviewed medical literature or official health authority publications. No commercial sources included.